Premium
Evaluation of Butaclamol in Chronic Schizophrenic Patients
Author(s) -
CLARK MERVIN L.,
PAREDES ALFONSO,
COSTILOE J. PAUL,
WOOD FREDDA
Publication year - 1977
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1977.tb05646.x
Subject(s) - placebo , chlorpromazine , medicine , antipsychotic drug , extrapyramidal symptoms , antipsychotic , incidence (geometry) , anesthesia , psychiatry , schizophrenia (object oriented programming) , mathematics , alternative medicine , geometry , pathology
In a double-blind, placebo-controlled study, an attempt was made to evaluate butaclamol in chronic schizophrenic patients using chlorpromazine (CPZ) as the standard comparative drug. With doses up to 50 mg/day, butaclamol was shown to have significant antipsychotic activity comparable to CPZ but with a much higher incidence of extrapyramidal signs. A more reasonable maintenance dose may be in the range of 5 to 20 mg/day. Rebound insomnia was noted again with butaclamol, which warrants further study.